Blue light bronchoscopy using sodium fluoresceinate can detect bronchial abnormalities. However, fluorescence is not specific for carcinoma, and moderate fluorescence is difficult to interpret, suggesting biopsies should be targeted.
Area of Science:
Pulmonology
Oncology
Medical Imaging
Background:
Bronchoscopy is a key diagnostic tool for lung diseases.
Blue light imaging with fluorescent agents may enhance visualization of bronchial abnormalities.
Purpose of the Study:
To evaluate the diagnostic utility of blue light bronchoscopy with sodium fluoresceinate in detecting bronchial carcinoma and other pathological changes.
Main Methods:
34 patients undergoing bronchoscopy (11 with bronchial carcinoma) received sodium fluoresceinate.
Bronchoscopy was performed using white light and then blue light.
Fluorescence was graded visually, and 76 biopsy specimens were collected from fluorescent and non-fluorescent areas.
Main Results:
Of 38 biopsies from fluorescent areas, 11 showed carcinoma, 10 moderate inflammation, 10 severe inflammation, and 1 tuberculosis.
Of 38 biopsies from non-fluorescent areas, 34 were normal, 3 showed slight inflammation, and 1 showed tumor.
Metaplasia was more frequent in fluorescent areas in smokers.
Conclusions:
Bronchial fluorescence is related to vascular changes and is not specific for carcinoma.
Highly fluorescent areas often indicate pathology, but moderate fluorescence is ambiguous.
Targeted biopsies of clearly fluorescent areas are recommended, as sampling every fluorescent area may be excessive.